226 related articles for article (PubMed ID: 33994172)
1. Angiogenesis, programmed death ligand 1 (PD-L1) and immune microenvironment association in laryngeal carcinoma.
Franz L; Alessandrini L; Calvanese L; Crosetta G; Frigo AC; Marioni G
Pathology; 2021 Dec; 53(7):844-851. PubMed ID: 33994172
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.
Franz L; Alessandrini L; Fasanaro E; Gaudioso P; Carli A; Nicolai P; Marioni G
Ann Diagn Pathol; 2021 Feb; 50():151657. PubMed ID: 33189034
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma.
Alessandrini L; Franz L; Ottaviano G; Ghi MG; Lanza C; Blandamura S; Marioni G
Oral Oncol; 2020 Sep; 108():104836. PubMed ID: 32512470
[TBL] [Abstract][Full Text] [Related]
4. Postoperative radiotherapy for laryngeal cancer. The prognostic role of programmed death-ligand 1: An immune microenvironment-based cluster analysis.
Franz L; Alessandrini L; Ottaviano G; di Carlo R; Fasanaro E; Ramacciotti G; Contro G; Marioni G
Pathol Res Pract; 2020 Sep; 216(9):153120. PubMed ID: 32825972
[TBL] [Abstract][Full Text] [Related]
5. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of CD103
Smith JD; Bellile EL; Ellsperman SE; Heft-Neal ME; Mann JE; Birkeland AC; Hoesli RC; Swiecicki PL; Worden FP; Schonewolf C; Shah JL; Mierzwa ML; Rosko AJ; Stucken CL; Chinn SB; Shuman AG; Casper KA; Malloy KM; Prince MEP; Wolf GT; Thomas DG; McHugh JB; Chad Brenner J; Spector ME
Oral Oncol; 2022 Dec; 135():106226. PubMed ID: 36323071
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
8. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
9. Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma.
Souza VG; Santos DJS; Silva AG; Ribeiro RIMA; Loyola AM; Cardoso SV; Miranda CSS; Cardoso LPV
J Appl Oral Sci; 2022; 30():e20210344. PubMed ID: 35195152
[TBL] [Abstract][Full Text] [Related]
10. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
12. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
14. Programmed Death Ligand 1 (PD-L1) Expression and CD8 + Tumor-infiltrating Lymphocyte-based Tumor Immune Microenvironment Classification in Gynecologic Carcinosarcoma: Prognostic Impact and Implications for Therapy.
Ordner J; Gutierrez Amezcua JM; Marcus A; Shukla PS
Int J Gynecol Pathol; 2023 Jul; 42(4):364-375. PubMed ID: 35639400
[TBL] [Abstract][Full Text] [Related]
15. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of PD-L1 Immunohistochemical Marker in Gastric Carcinoma and Its Correlation with HER2 Status.
Attia S; Abd El Hafez A; Abdel-Aziz A; Elmetwaly S; Mokhtar N
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1433-1444. PubMed ID: 35485706
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
18. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
